基于 AGREE II 的急性冠脉综合征患者抗血小板 药物治疗的指南评价.

OBJECTIVE: To evaluate the clinical practice guidelines for antiplatelet therapy in patients with acute coronary syndrome (ACS) published domestically and internationally from 2010 to 2019 according to appraisal of guidelines for research and evaluation Ⅱ (AGREE Ⅱ) tool. METHODS: Guidelines and related literature for the treatment of antiplatelet drugs in patients with ACS published domestically and internationally from 2010 to 2019 were selected as the research object, and AGREE Ⅱ was used to perform systematic review, and the differences between recommended contents of the guidelines were analyzed. RESULTS: A total of 10 relevant guidelines were included, including 7 treatment guidelines and 3 expert recommendations and consensus. Mean scores for each domain of AGREE Ⅱ were (82. 5±8. 7)% for scope and purpose, (67. 5±15. 3)% for participants, (68. 7±18. 2)% for rigor of formulation, ( 89. 3 ± 4. 0)% for clarity of presentation, ( 68. 1 ± 13. 8)% for applicability, ( 54. 8 ± 12. 3)% for editorial independence, and (65. 7±12. 3)% for overall evaluation. The intra-group correlation coefficient and 95%CI was 0. 89 ( 0. 72-0. 92), indicating a high degree of consistency in researcher scores. All guidelines recommend aspirin + P2Y12 receptor antagonist combined with antiplatelet therapy after surgery. CONCLUSIONS: Clinical guidelines recommend aspirin + P2Y12 receptor antagonist combined with antiplatelet therapy for 12 months. Genetic testing is not necessary in patients with ACS. [ABSTRACT FROM AUTHOR]